AUS
NZ
UK
CA
USA
IND
ResMed CDI has seen a notable 27.8% rise in its share price in 2024, reflecting strong market confidence in the Australian market. Meanwhile, Pilbara Minerals Ltd has managed to rebound significantly, trading about 45% above its 52-week low. This article provides a brief overview of their recent performance and current valuations within the context of the Australian stock market.
Resmed CDI (ASX:RMD)
The Resmed CDI share price has experienced a notable increase of 27.8% since the beginning of 2024. Founded in Australia in 1989 by Peter Farrell, Resmed is now headquartered in San Diego, California. The company specializes in medical equipment, primarily offering cloud-connectable continuous positive airway pressure (CPAP) machines for the treatment of obstructive sleep apnea (OSA).
Resmed operates globally with over 10,000 employees across more than 140 countries. Its business is divided into two main units: Sleep and Respiratory Care and Software as a Service (SaaS). The Sleep and Respiratory Care unit provides leading CPAP machines and other respiratory devices, supporting patients from those needing nightly therapy to those requiring life-support ventilation. The SaaS unit focuses on durable and home medical equipment, enhancing out-of-hospital care with its digital health network and cloud-connected devices.
The company's extensive digital health network, driven by its advanced hardware and SaaS data, allows Resmed to offer valuable insights, improve patient outcomes, and reduce healthcare costs.
Pilbara Minerals Ltd (ASX:PLS)
On the other hand, Pilbara Minerals Ltd has seen its share price remain about 45% above its 52-week low. Pilbara Minerals is a leading Australian lithium company, known for owning 100% of the Pilgangoora lithium project, the world’s largest independent hard-rock lithium operation, which it acquired in 2014.
Pilbara's core business involves mining and selling spodumene concentrate. The company markets its concentrate through offtake agreements and spot sales on the Battery Material Exchange (BMX) platform. Notable offtake partners include major companies like Great Wall and POSCO.
Despite overcoming significant challenges to become a leader in lithium mining, Pilbara’s revenue remains subject to the fluctuations in the global price of spodumene. However, its role as a key player in the lithium market aligns it well with the growing demand for electric vehicles and battery technologies.
For Resmed CDI, evaluating the share price involves examining the price-to-sales (P/S) ratio. Currently, Resmed CDI shares have a P/S ratio of 4.89x, which is below its 5-year average of 7.81x. This suggests that the shares are trading at a lower valuation compared to their historical average. It’s important to consider multiple factors and valuation techniques when assessing investment opportunities, as relying on a single metric may not provide a complete picture.
Both Resmed CDI and Pilbara Minerals Ltd showcase distinct market positions—Resmed in medical technology and Pilbara in lithium mining. Their performances reflect different aspects of their respective industries, offering diverse insights into their current and future prospects.
